ESMO Congress 2026Watching

deuderuxtecan

5 reports2 sourcesupdated 1 day ago

Start here

No synthesis yet — start with the coverage timeline below.

Coverage timeline

Follow the coverage to see the different angles.

Oct 24

02:09
x.com
Impressive #APEXBreast01 data showing benefit with rolditamig deuderuxtecan over first-line chemotherapy in HR+/HER2-low metastatic #BreastCancer!

Oct 23

20:08
x.com
APEX Breast01
20:04
x.com
APEX Breast01
20:03
x.com
#APEXBr01: Rolditamig deuderuxtecan - ECD2 and ECD4 HER-2 ADC, DAR ~ 6

Oct 20

18:57
mp.weixin.qq.com

Heat trend for this story

Heat now 11·Peak in the comparable set 27 (Oct 24 03:00)·Change over 24h in the comparable set -50%·Participants now 4

Participants counted4

Heat over time

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.